Education
About Us
Working with TipRanks
Follow Us
IceCure Medical (ICCM)
NASDAQ:ICCM
Earnings Data
Report Date
May 14, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.08Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 14, 2025
Earnings Call Sentiment|Neutral
IceCure Medical Ltd demonstrated strong sales growth and positive developments in product adoption and support from the FDA advisory panel, while facing challenges with a delayed FDA decision and increased net losses. The financial improvements in gross profit and margin were positive indicators, yet the increase in operating expenses and net loss were areas of concern.Company Guidance
During the call, IceCure Medical Ltd provided guidance on several key metrics and developments. The company reported a notable 42% year-over-year increase in product sales in North America, contributing to an overall product sales increase of 8% to $3.19 million for the fiscal year ending December 31, 2024. Total revenue rose slightly to $3.29 million, with gross profit up by 12% to $1.45 million, resulting in an improved gross margin of 44%. Non-GAAP gross profit saw a 32% increase to $1.35 million, with a non-GAAP gross margin of 42%. Operating expenses rose by 2% to $17.15 million, while net loss increased by 5% to $15.32 million. The company held cash and cash equivalents of approximately $7.6 million as of December 31, 2024, and $6 million as of March 24, 2025. Additionally, IceCure raised $2.6 million in net proceeds through sales of ordinary shares. The company remains optimistic about a favorable FDA decision regarding the ProSense device for early-stage low-risk breast cancer and anticipates several catalysts, including regulatory filings in Japan and China, and further data from third-party studies.Significant Increase in Product Sales
IceCure Medical Ltd reported a 42% increase in product sales in North America, with global sales momentum continuing in Europe, Japan, and other regions.
Expansion and Adoption of ProSense
ProSense cryoablation saw increased adoption in various indications worldwide, with 33 investigator-initiated studies, mostly in breast cancer, published in 2024.
FDA Advisory Panel Support
The FDA Medical Device Advisory Committee panel voted in favor of ProSense's Benefit-Risk Profile for early-stage low-risk breast cancer, indicating potential for future approval.
Improved Financial Metrics
Gross profit increased by 12% to $1.45 million, with gross margin rising to 44% from 40% year-over-year. Non-GAAP gross profit increased by 32% to $1.35 million.
---
ICCM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ICCM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $1.14 | $1.10 | -3.51% |
| Nov 26, 2024 | $0.78 | $0.79 | +1.28% |
| Aug 20, 2024 | $0.64 | $0.75 | +17.19% |
| May 28, 2024 | $1.03 | $1.04 | +0.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does IceCure Medical (ICCM) report earnings?
IceCure Medical (ICCM) is schdueled to report earning on May 14, 2025, TBA Not Confirmed.
What is IceCure Medical (ICCM) earnings time?
IceCure Medical (ICCM) earnings time is at May 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICCM EPS forecast?
ICCM EPS forecast for the fiscal quarter 2025 (Q1) is -0.08.
---